Therefore, despite clear biological differences between CRC and the malignancies with a high prevalence of IDH mutations, cautious exploration of the efficacy of mutant IDH inhibitors and DNA demethylating agents is arguably warranted in IDH‐mutant CRCs. Here, IDH2 is linked to colorectal carcinoma.